United States · Texas · trialsVeterans, ibogaine and a serious research commitment
Texas enacted SB 2308 to support FDA drug-development trials of ibogaine for opioid use disorder and other conditions where evidence may emerge. The human story is powerful: veterans with traumatic brain injury and PTSD symptoms need better options. A small, prospective observational study of 30 special-operations veterans reported improvements after a magnesium–ibogaine protocol.
The limit: that study had no randomised control group. Ibogaine can affect heart rhythm, so closely monitored trials matter. Texas did not broadly legalise psilocybin or approve ibogaine as routine PTSD care.
United States · cannabis · regulationA federal opening for medical cannabis research
The U.S. has taken a narrower medical-cannabis scheduling step while considering broader rescheduling. This could make research and regulated access easier. Some specific cannabinoid medicines already have FDA approvals for particular seizure disorders, chemotherapy-related nausea, and appetite loss in AIDS.
The limit: rescheduling is not nationwide recreational legalisation, and an approved medicine does not validate every cannabis product or health claim. Evidence and harms vary by formulation, dose and condition.
Thailand · access · changing rulesFrom open storefronts to medical controls
Thailand's rapid cannabis policy shift showed how quickly access can change. The current guidance restricts use to medical purposes with a Thai-issued prescription. This is a useful case study in balancing patient access, product quality and public-health concerns.
The limit: the storefront era should not be described as today's legal position. Recreational use remains illegal under current guidance; visitors must check local rules before buying, using or travelling with cannabis.
Mexico · regenerative medicine · verificationStem cells: ask which approval, for what purpose
Mexico has a regulatory route for establishments handling stem cells and regenerative medicine. That can support legitimate clinical work and careful patient oversight. It does not mean every advertised stem-cell treatment has been proven or approved for every condition.
The limit: we have not verified a new blanket approval of stem-cell therapy in Mexico. A clinic licence, a registered study and authorisation of a specific treatment are different things. We will update this story when a named therapy, indication and regulator decision can be confirmed.
Evidence desk · nicotine and cognitionOne molecule, a worthwhile question, and real tradeoffs
Dave Asprey has argued for separating nicotine itself from the harms of smoking. That distinction is useful for research: nicotine has shown short-term effects on attention and some memory tasks, and a registered trial is testing a transdermal patch in people with mild cognitive impairment. We will add a specific episode once its guest and claims have been checked against the original transcript and research.
The limit: short-term task effects do not establish prevention of dementia, longevity benefit or a safe wellness routine. Nicotine is addictive; smoking and vaping are not routes we recommend. The trial's outcome and applicability to healthy people must be checked before making broader claims.